243 related articles for article (PubMed ID: 27016228)
21. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
22. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
23. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
25.
Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
[TBL] [Abstract][Full Text] [Related]
26. Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.
Lacey JV; Yang H; Gaudet MM; Dunning A; Lissowska J; Sherman ME; Peplonska B; Brinton LA; Healey CS; Ahmed S; Pharoah P; Easton D; Chanock S; Garcia-Closas M
Gynecol Oncol; 2011 Feb; 120(2):167-73. PubMed ID: 21093899
[TBL] [Abstract][Full Text] [Related]
27. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Fiorica JV; Brunetto VL; Hanjani P; Lentz SS; Mannel R; Andersen W;
Gynecol Oncol; 2004 Jan; 92(1):10-4. PubMed ID: 14751131
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Moroney JW; Schlumbrecht MP; Helgason T; Coleman RL; Moulder S; Naing A; Bodurka DC; Janku F; Hong DS; Kurzrock R
Clin Cancer Res; 2011 Nov; 17(21):6840-6. PubMed ID: 21890452
[TBL] [Abstract][Full Text] [Related]
31. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K; Stokoe D; Taketani Y; McCormick F
Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209
[TBL] [Abstract][Full Text] [Related]
32. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
34. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
[TBL] [Abstract][Full Text] [Related]
35. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
[TBL] [Abstract][Full Text] [Related]
36. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Rothé F; Laes JF; Lambrechts D; Smeets D; Vincent D; Maetens M; Fumagalli D; Michiels S; Drisis S; Moerman C; Detiffe JP; Larsimont D; Awada A; Piccart M; Sotiriou C; Ignatiadis M
Ann Oncol; 2014 Oct; 25(10):1959-1965. PubMed ID: 25185240
[TBL] [Abstract][Full Text] [Related]
37. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
[TBL] [Abstract][Full Text] [Related]
39. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
[TBL] [Abstract][Full Text] [Related]
40. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
